← back to the index
DV-004 cardiac electrophysiology 2007

The Sprint Fidelis Lead — the Thin Wire That Shocked, Failed, and Stayed Inside

deathinappropriate-shockmechanical-fracturetherapy-failurecardiac-electrophysiologycardiology2000s2010s
Patients implanted
~268,000 leads implanted worldwide (majority U.S.)
Failure or harm
~2.3% fracture by 30 mo (Medtronic); 3.75%/yr independently; 13+ deaths linked
In use
~3 yrs (Sep 2004 – Oct 15, 2007)
Status
Recalled (Class I)

Summary

When Medtronic Inc. suspended distribution of the Sprint Fidelis defibrillator lead on 15 October 2007, the gap between what the device promised and what it delivered was already measured in patients shocked awake by a machine guarding a heart that never faltered — and in others whose hearts stopped while a fractured wire stood silent. The Fidelis (models 6930, 6931, 6948, 6949) had been marketed since September 2004 as a refinement of an unglamorous component: the insulated wire that carries the sensing and high-voltage shock between an implantable cardioverter-defibrillator and the heart muscle. Its selling proposition was caliber. At 6.6 French — roughly 2.2 millimeters — it was the thinnest defibrillation lead on the market, slimmer than Medtronic's own proven Sprint Quattro and easier to thread into the right ventricle. Thinner was sold as better. Thinner was the defect.

The harm took two mirror-image forms. When a Fidelis conductor fractured — and the thin, integrated cables fractured at higher-than-baseline rates near the can and the anchor sleeve — the lead generated electrical noise the ICD misread as a lethal arrhythmia, and the device did what it was built to do: it delivered a 30-to-40-joule shock into a fully conscious patient, sometimes dozens of times in a night. The opposite failure was worse. A fractured conductor could also break the circuit, so that when the patient genuinely arrested, the defibrillator could not deliver the therapy that was its entire reason to exist. Medtronic's own analysis projected roughly 2.3 percent of leads fracturing within 30 months; independent center series ran far higher, near 3.75 percent per year against 0.6 percent for comparison leads. At least 13 deaths were ultimately linked to the lead.

Medtronic halted sales and recalled all unimplanted Fidelis leads; the FDA designated it Class I, its most serious category, reserved for products that may cause serious injury or death. But the defining feature was what did not happen: the roughly 268,000 leads already inside patients' chests were largely left there. A defibrillator lead becomes encased in scar and bonded to the heart wall within months, and extraction can tear the vena cava or ventricle and kill the patient on the table. The recall could not undo itself. Patients were handed a probabilistic dilemma — leave a wire with a known, accelerating failure rate, or accept the lethal risk of pulling it — and a management tail that fell heavily on Medicare. A 2010 settlement of roughly 8,100 lawsuits for $268 million closed the litigation; it did not close the chests.

Timeline

2001
The proven predecessor
Medtronic's Sprint Quattro defibrillation lead, near 8 French, establishes a record of reliable performance and becomes the benchmark the Fidelis is built to slim down.
Sep 2004
Fidelis launches
Medtronic releases the Sprint Fidelis family (6930/6931/6948/6949) at 6.6 French — the thinnest ICD lead available — marketed for easier implantation. It rapidly becomes the company's default lead.
2004–2007
Mass implantation
More than 268,000 Fidelis leads are implanted worldwide over roughly three years, the great majority in the United States.
Early 2007
Hauser's signal
Dr. Robert G. Hauser of the Minneapolis Heart Institute analyzes returned-product and registry data showing elevated fracture and inappropriate-shock rates, and raises the finding with Medtronic.
Apr 13, 2007
Published warning
Hauser's analysis of lead-failure cases appears in Heart Rhythm, putting the elevated fracture concern into the peer-reviewed literature months before any recall.
Mid-2007
Sales continue
Despite the surfacing data, Fidelis leads remain in active distribution and implantation through the summer of 2007.
Oct 15, 2007
Distribution suspended
Medtronic voluntarily stops selling the Fidelis and recalls all unimplanted leads, citing an abnormally high fracture rate; the FDA classifies it Class I.
Oct 2007
The retrieval problem
Guidance advises against routine prophylactic extraction of implanted leads because removal risk exceeds the fracture risk for most patients; the ~268,000 in-body leads stay in place.
2008–2011
Failure curve climbs
Center series and registry data confirm Fidelis fracture rates rising over time — an accelerating, not flat, hazard — with independent annual rates near 3.75% versus ~0.6% for control leads.
2010
Five-year Medicare cost quantified
A peer-reviewed analysis estimates the initial five-year cost to Medicare of managing the recall — monitoring, replacements, and complications — in the hundreds of millions of dollars.
2010
The $268M settlement
Medtronic settles roughly 8,100 personal-injury suits for about $268 million; courts had earlier dismissed many claims as federally preempted under Riegel v. Medtronic (2008).
2014–2015
The tail persists
Studies of laser lead extraction seven years post-recall document continued fractures and the ongoing clinical burden of leads that were never removed.

The Caliber That Sold the Lead

The Sprint Fidelis was a real answer to a real ergonomic problem, and the wrong answer to it. Defibrillation leads are stiff, multi-conductor cables that must be navigated through the subclavian vein, across the tricuspid valve, and screwed into the right ventricular wall; a thinner lead is genuinely easier to place and route. Medtronic engineered the Fidelis down to 6.6 French, materially slimmer than the roughly 8-French Sprint Quattro it descended from, and launched it in September 2004 on that premise. Achieving the slimmer profile meant consequential changes: the crush lumens kept separate in the Quattro were integrated, the coil insulation moved from PTFE to ETFE, and the conductor cables themselves were finer. Each modification served the diameter target. None had been proven, over years of in-body service, to tolerate the relentless mechanical cycling of a wire that flexes with every heartbeat — on the order of 40 million times a year — at the high-stress points where it bends near the can and the suture sleeve. The marketing virtue and the failure mechanism were the same feature.

The Two Failures and the Conscious Shock

What made the Fidelis fracture an emergency rather than a maintenance issue was the symmetry of its consequences. A defibrillator lead does two opposite jobs through the same wires: it listens to the rhythm continuously, and on command delivers a massive shock. A fracture corrupted both. On the sensing side, a broken or intermittently contacting conductor produced electrical artifact the ICD's algorithm could not distinguish from ventricular fibrillation; the device charged and fired. Patients with normal rhythms were knocked down by 30-to-40-joule discharges while fully awake, sometimes in storms of a dozen or more shocks, an experience survivors likened to being kicked in the chest by a horse. On the therapy side, the same fracture could open the high-voltage circuit, so the one moment the device existed for — a real cardiac arrest — arrived with the shock pathway severed. The signal existed before the recall: Dr. Robert Hauser's analysis reached Heart Rhythm in April 2007 and reached Medtronic earlier still. Distribution continued into October. The hazard was characterized, inside and outside the company, months before the leads were pulled.

The Recall That Could Not Reverse Itself

The 15 October 2007 action exposed the central asymmetry of implanted-device failure: a recall retrieves only what has not yet been used. Medtronic could stop shipping leads and reclaim unimplanted inventory, and the FDA could brand the recall Class I, but the roughly 268,000 leads already bonded into patients' hearts were another matter. Within months a lead is encapsulated in fibrous scar and adherent to the endocardium; extraction requires specialized laser or mechanical sheaths and risks tearing the great vessels or ventricular wall, with procedural mortality that across a population would plausibly exceed the deaths the fractures themselves would cause. The consensus that emerged was to leave most leads in place and monitor — a defensible aggregate calculation that left every individual patient carrying a wire with a known, rising probability of failing in one of two catastrophic directions. The legal reckoning compounded the sense of a system without recourse: the Supreme Court's 2008 Riegel v. Medtronic decision held that FDA premarket approval preempted most state-law claims, dismissing thousands of suits before they were heard. The survivors settled in 2010 for about $268 million across roughly 8,100 plaintiffs. The leads stayed; the courthouse closed.

Contributing Factors

01
Optimizing a single attribute past the failure point
The Fidelis was designed to a diameter target — thinnest on the market — and every structural change that served thinness (integrated crush lumens, finer conductors, altered insulation) traded away mechanical durability that only years of cyclic in-body loading would test. Optimizing one marketable dimension while the load-bearing one degrades silently is the recurring engineering trap; the headline virtue was the latent defect.
02
Cyclic-fatigue failure that bench testing underweights
A defibrillation lead flexes tens of millions of times a year at fixed high-stress points. Accelerated bench protocols and short premarket follow-up could not surface a hazard that manifests as a rising fracture curve over 24-to-36 months. The failure was time-dependent and load-dependent — exactly the class of defect that escapes a launch and only appears once a large cohort has been in service for years.
03
A safety signal that surfaced before the sales stopped
Dr. Robert Hauser's elevated-fracture analysis was discussed with Medtronic in 2007 and published in Heart Rhythm in April 2007, yet Fidelis distribution continued until October. The lag between a credible external signal and the market action it warranted let additional tens of thousands of leads enter patients who could have been spared.
04
Recall without retrieval
Suspending sales and reclaiming shelf stock did nothing for the ~268,000 leads already encapsulated in patients' hearts, which could not be safely removed en masse. Treating cessation of distribution as the remedy — when the hazard lived inside the body and extraction itself could kill — left a probabilistic burden on individual patients and a multi-hundred-million-dollar management tail on Medicare.
05
Preemption as a liability firewall
The 2008 Riegel v. Medtronic ruling that FDA premarket approval bars most state-law claims converted the regulatory clearance the Fidelis had passed into a shield against the injuries it caused. A manufacturing-and-design failure was substantially insulated from tort accountability by the very approval that let it reach the market, and the residual claims resolved for a sum modest against the scale of exposure.

Aftermath

The Fidelis reframed how the cardiac-device field thinks about leads. Its most durable consequence was epistemic: it demonstrated that a lead's true reliability is unknowable at launch and can only be read from a rising failure curve years into broad use — and that the surveillance system must therefore be treated as part of the device, not an afterthought. The episode, alongside the parallel St. Jude Riata recall that followed, drove the build-out of remote-monitoring networks, lead-performance registries, and the expectation that makers publish ongoing survival-probability data. The financial reckoning — roughly $268 million across about 8,100 suits, with thousands more claims extinguished by preemption — was small relative to the in-body population at risk, a disparity that became its own argument over whether premarket approval should immunize device makers from tort liability. And the leads endured: a decade on, patients still carried Fidelis conductors, and extraction studies were still measuring the cost of wires that could neither be trusted nor safely removed. Today the Sprint Fidelis is the byword for the thinner-is-better defibrillator lead — the refinement that fractured, the recall that could not reach inside the chest, and the proof that for an implanted device, withdrawal from sale is the beginning of the problem, not the end.

Lessons

  1. Distrust any safety-critical component optimized toward a single marketable attribute; ask which load-bearing property was traded to achieve it, and assume that property is where the failure will originate.
  2. For a device that cycles mechanically millions of times in service, treat short premarket follow-up and accelerated bench testing as incapable of certifying durability — require a survival curve from real cohorts before declaring the design proven.
  3. When a credible external safety signal surfaces, measure the cost of delay in units that keep entering patients; every month of continued distribution after the signal is an irreversible decision against the next cohort.
  4. Separate recall from retrieval explicitly: if the hazard lives inside the body and removal is itself dangerous, stopping sales is not a remedy, and the obligation is to fund the monitoring and management of what cannot be taken back.
  5. Read regulatory clearance as a floor, not a shield — premarket approval that later immunizes you from liability also removes the corrective pressure that liability supplies, so build the post-market surveillance you would want if no preemption existed.

References